COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases : insights from the COVAD study

Show simplified metadata
dc.contributor.affiliationUniversity of L'Aquila and San Salvatore Hospital; Leeds Teaching Hospitals Trust; University of Leeds; Sandwell and West Birmingham NHS Trust; et al.en_US
dc.contributor.authorAlunno, Alessia
dc.contributor.authorCarubbi, Francesco
dc.contributor.authorTan, Ai Lyn
dc.contributor.authorSen, Parikshit
dc.contributor.authorCavagna, Lorenzo
dc.contributor.authorJoshi, Mrudula
dc.contributor.authorDay, Jessica
dc.contributor.authorSaha, Sreoshy
dc.contributor.authorGutiƩrrez, Carlos Enrique Toro
dc.contributor.authorCaballero-Uribe, Carlo Vinicio
dc.contributor.authorDistler, Oliver
dc.contributor.authorChinoy, Hector
dc.contributor.authorAggarwal, Rohit
dc.contributor.authorAgarwal, Vikas
dc.contributor.authorGupta, Latika
dc.contributor.departmentRheumatologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.trustauthorGupta, Latika
dc.date.accessioned2024-09-17T13:01:52Z
dc.date.available2024-09-17T13:01:52Z
dc.date.issued2024-07-13
dc.description.abstractNotwithstanding the wealth of literature on COVID-19, studies focusing on young adults with autoimmune diseases (AD) are lacking. To determine early (within 7 days) and late (after 7 days) anti-SARS-CoV-2 vaccine-related adverse events (AEs), post-vaccine disease flares, COVID-19 severity and breakthrough infections (B-INFs) in young people with rheumatic diseases (RMDs) and non-rheumatic autoimmune diseases (nr-ADs) compared to healthy controls (HC). Data were captured through the international COVID-19 vaccination in autoimmune diseases (COVAD) 1 and 2 questionnaires. Of 20,685 complete responses, we identified 6010 from patients aged 18-35 years (1692 RMD, 400 nrADs, 3918 HC) who received up to 4 vaccine doses. BNT162b2 was the most frequently administered vaccine and prior to vaccination, 7% of people with nrAD were taking immunosuppressants (IS) versus 80% in RMDs. Early mild AEs were more frequent in RMDs (93%) and nr-ADs (92%) compared to HC (85%). The frequency of late mild AEs was < 20% in all groups. Severe AEs were rare. SARS-CoV-2 infection rates were similar across all groups, however, RMD patients reported a single episode of infection more frequently than nrADs and HC, while nrADs reported multiple infections more frequently than RMD. Self-reported disease flares were reported by 10% or RMD and 7% of nrAD patients. Our study reinforces the safety of anti-SARS-CoV-2 vaccine also in young people with ADs, but it also highlights that among young individuals the number and clinical picture of SARS-CoV-2 infections is affected more by the type of AD rather than by coexisting IS therapy.en_US
dc.identifier.citationAlunno A, Carubbi F, Tan AL, Sen P, Cavagna L, Joshi M, Day J, Saha S, GutiƩrrez CET, Caballero-Uribe CV, Distler O, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD Study Group. COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD study. Rheumatol Int. 2024 Sep;44(9):1725-1731. doi: 10.1007/s00296-024-05654-w. Epub 2024 Jul 13en_US
dc.identifier.urihttp://hdl.handle.net/20.500.14200/5772
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.source.journaltitleRheumatology Internationalen_US
dc.subjectRheumatologyen_US
dc.titleCOVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases : insights from the COVAD studyen_US
dc.typeArticleen_US
dspace.entity.typePublication
oa.grant.openaccessnaen_US
rioxxterms.versionNAen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research (Articles)